Yan M et al. found that when osteosarcoma was treated with cisplatin, the UPR was activated, and both branches of PERK and IRE1 activated NF-κB, thus preventing the cells from acquiring chemoresistance to cisplatin [96]. Here, NFKB1 is linked to osteosarcoma.